Photobiomodulation for the Whole Body



GLOBAL LEADER: The ARRC LED is a world leader in whole body photobiomodulation or Red Near Infrared LED Light Therapy Beds. Our systems range from the mid dose, non-thermal EDGE POLY to our high dose ATP system. ARRC LED is and will continue to be an innovator and disrupter within this emerging industry. In 2019 alone we are introducing two new patent pending systems and initiating a number of clinical trials to evaluate how a whole body chamber affects the body.

BROAD MARKET: Our systems can be found in the homes of world leaders, corporate executives and in the training rooms of professional sports teams. Doctors are prescribing PBM for their patients, recovery centers are offering it for athletes and alternative health seekers. Spas are using PBM to help their clients look better from head to toe. The appeal of PBMt is broad.

INNOVATION: Researchers continue to conclude that the mechanisms behind PBMt are still uncertain. Our belief is that there are multiple wavelengths of energy that create slightly different healing signatures inside the body.  Green for example might differ in how it affects blood cells and therefor be more active for diabetic, neuropathy, acne and shingles patients.  Red and infrared both have their own healing signatures.  Even within each color, we believe that healing signatures vary.  420nm blue may be most effective for acne, while 450nm blue is better for SAD and 470nm blue is best for MRSA. They are all blue and each slight variation has different benefits.

US Manufactured LED Light Therapy Bed


The EDGE, EDGE POLY and ATP are engineered and designed in California.

Our systems are built in an ISO 9001, Military and FDA compliant manufacturing facility according to GMP, FDA Quality Management Systems and ISO protocols.

The ARRC LED is FDA Registered. The FDA allows for low level light therapy devices to be sold ‘over the counter’ (FDA Exempt), with the only claim of ‘minor aches and pains’.

The ARRC LED makes no claims as to the effectiveness of its systems for any condition other than minor aches and pains. Always consult with your doctor when treating a medical condition. The ARRC LED does not offer any medical advice, always consult with your physician when treating a condition.. 


The mission of ARRC LED is to lead in PBMt technology and, present this technology to multiple demographics that are both affordable and highly effective.


  • In April of 2019 the ARRC LED will introduce two systems for clinical trials and testing. At present the clinical trials will be in Southern CA, West Virginia and New Jersey. A new round of trials in the fourth quarter will be designed to evaluate the effectiveness of the new ATP RF and ATP PRO systems.

  • If you are a potential research subject, who may suffer from chronic pain, arthritis, diabetes or fibromyalgia and you live near the 3 areas highlighted above please reach out to thearrcled@gmail.com and address the email to Clinical Trials.

  • The trial will require 2 - 3 sessions per week lasting approximately 15 minutes each.

  • A small fee may be charged by the facility holding the clinical trial to cover expenses

  • These will be published but no personal indicators will be taken, meaning none of your personal information will be wither recorded or published.



Read what researchers from Mass General, Harvard and Boston University conclude about LED Light Therapy. We are excited to add Dr Michael Hamblin arguably the world’s leading expert on PBMt to our mix of phd’s, engineers and slightly crazy innovators!

Dr Hamblin ARRC LED Consultant

There have been a large number of both animal model and clinical studies that demonstrated highly beneficial LLLT effects on a variety of diseases, injuries, and has been widely used in both chronic and acute conditions (see Figure 7). LLLT may enhance neovascularisation, promote angiogenesis and increase collagen synthesis to promote healing of acute (Hopkins et al. 2004) and chronic wounds (Yu et al. 1997). LLLT provided acceleration of cutaneous wound healing in rats with a biphasic dose response favoring lower doses (Corazza et al. 2007). LLLT can also stimulate healing of deeper structures such as nerves (Gigo-Benato et al.2004), tendons (Fillipin et al. 2005), cartilage (Morrone et al. 2000), bones (Weberet al. 2006) and even internal organs (Shao et al. 2005). LLLT can reduce pain (Bjordal et al. 2006a), inflammation (Bjordal et al. 2006b) and swelling (Carati et al. 2003) caused by injuries, degenerative diseases or autoimmune diseases. Oron reported beneficial effect of LLLT on repair processes after injury or ischemia in skeletal and heart muscles in multiple animal models in vivo (Ad and Oron 2001;  Oron et al. 2001a;   Oron et al. 2001b;  Yaakobi et al. 2001). LLLT has been used to mitigate damage after strokes (in both animals (Lapchak et al. 2008) and humans (Lampl et al. 2007)), after traumatic brain injury (Oron et al. 2007) and after spinal cord injury (Wu et al. 2009).

Beneficial tissue effects of LLLT can include almost all the tissues and organs of the body.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790317/ 2.8. Downstream cellular response